

# PATHWAY AND DISEASE MODELING

June 19-21, 2006 • The Fairmont Hotel • San Francisco, CA

## EXPRESSION PROFILING DATA ANALYSIS

From Probes to Pathways

*Dr. Hugh Salamon, Senior Scientist, Computational Biology, Berlex Biosciences*

Identifying Nodal Involvement from Primary Tumor Tissue

*Mr. Bill Worzel, Chief Technology Officer, Genetics Squared*

Quantification of Nucleic Acids from Heterogeneous Clinical Samples

*Dr. Philip Day, Senior Lecturer, Medicine, University of Manchester*

## BIOMARKER IDENTIFICATION FROM EXPRESSION DATA

Mechanistic Biomarkers - Delivering Success Beyond Correlation

*Dr. Keith Elliston, President & CEO, Genstruct, Inc.*

Use of Network-Based Approaches to Develop Biomarkers for Drug Development

*Dr. John R. Lamb, Associate Scientific Director, Research Genetics, Rosetta InPharmatics, A wholly owned subsidiary of Merck & Co.*

## MODELING PATHWAY MODULATION BY DRUGS

Predictive Integrative Biology and Downstream Experimental Testing: A Synergistic Paradigm that Deciphers Complex Pathological Processes and Modes of Drug Action

*Dr. Francois Iris, President & CSO, Bio-Modeling Systems*

The Generation and Use of Regulatory Gene Networks in Endothelial Cells

*Dr. Stephen Charnock-Jones, Co-Founder, GNI Ltd. and University Reader, Obstetrics and Gynecology, University of Cambridge*

## MODELING SIGNALING PATHWAYS

From Critical Pathway Identification to a Computational Model and its Application to Biomarker Identification

*Dr. Birgit Schoeberl, Director, Network Biology, Merrimack Pharmaceuticals*

RepairCHIP: A New Platform to Explore the Activated Pathways in Cancer

*Dr. Jan Feng, Associate Professor, Chemistry, Temple University*

The Current Model of the NF-kappaB Pathway: Theory Entwined with Experiments

*Dr. Andre Levchenko, Assistant Professor, Biomedical Engineering, Johns Hopkins University*

## UNDERSTANDING CANCER MECHANISM FROM EXPRESSION DATA

Uveal Melanoma: Molecular Networks Underlying Extracellular Matrix Reorganization and Tumor Progression

*Dr. Zarema Arbieva, Assistant Professor & Director, Medicine, The University of Illinois at Chicago*

A Putative Signature of Chromosomal Instability Inferred from Gene-Expression

*Dr. Zoltan Szallasi, Senior Research Scientist, CHIP, Children's Hospital Boston*

## CANCER DISEASE MODELING

A Case Study for Integration Informatics: From Data Integration and Management to Marker-Based Diagnostics Models

*Mr. Robert Stanley, Vice President, Chief Technology Officer, IO Informatics*

The Obsolescence of Reductionist Biology, Systems Biology Modeling and Cancer Cachexia Therapy Development Based on Emergent Patterns of Organization Rather than on Genes and Molecules

*Dr. Fredric Young, Chief Scientist, Biophysics, Vicus Therapeutics, LLC*

Calibrating Xenografts: Developing Virtual Tumors for Reduced Attrition

*Dr. John Savin, CEO, Physiomics plc*

*Courtesy of San Francisco Convention & Visitor's Bureau, Photo by P. Fuszard.*